Iremember being in a college pathology class when the professor told us we should learn about type 1 diabetes, since it was likely to impact someone we knew. Then he said something else that I didn’t fully understand at the time: the insulin market was becoming more concentrated, with fewer companies producing it, which was leading to fewer options and rising prices.

Fast forward nearly 30 years later, and my 13-year-old daughter was diagnosed with type 1 diabetes.

We struggled at first. But after a few difficult months, we found a system that worked — involving lifestyle changes and the use of a specific long-acting insulin called Levemir (detemir).

Levemir has a shorter and more predictable action than the few alternative long-acting insulins. That made it ideal for my daughter, an at

See Full Page